Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. [electronic resource]
Producer: 20121108Description: 1480-6 p. digitalISSN:- 1523-4681
- Aged
- Aged, 80 and over
- Algorithms
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Body Mass Index
- Bone Density Conservation Agents -- therapeutic use
- Denosumab
- Female
- Fracture Healing
- Humans
- Middle Aged
- Osteoporosis -- drug therapy
- Osteoporotic Fractures -- prevention & control
- Placebos
- Postmenopause
- Probability
- Proportional Hazards Models
- Risk
- Risk Assessment
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.